Below are shareholder questions submitted after the Annual Meeting that were not addressed during the live meeting.

Q. Although I am asking a question as a shareholder, I am asking it at the prompting of my high school aged children, and I would appreciate a response directed to their age group: Reputational risk is a component of financial risk. Does the Board see Company financial support for politicians who supported the January 6th, 2021 insurrection at the Capitol as a reputational risk, even if those politicians may support other initiatives supportive of the Company? At the end of the day, I as a shareholder and the Board as a group, have to look into the eyes of my high school age children and explain to them why the Company is making the choices it makes. I look forward to your response. Thank you.

A. Thank you for your question. Pfizer’s political expenditures align with the company’s public policy priorities. We operate in a highly regulated and competitive industry therefore we must engage on public policy issues that may affect our ability to meet patients’ needs and enhance shareholder value. These issues include advancing biomedical research and healthcare innovation; advocating for protecting intellectual property rights; and improving patient access to care.

All corporate and Pfizer Political Action Committee (PAC) political spending decisions undergo a rigorous review process conducted by the PAC Steering Committee comprised of colleagues from various divisions within Pfizer to ensure that each contribution we make is done to advance our business objectives, and is not based on the political preferences or views of any individual colleague within Pfizer. Pfizer has acknowledged in its Political Action Committee and Corporate Political Contributions Report, available at:
https://www.pfizer.com/about/corporate_governance/political_action_committee_report that we recognize that politicians have a range of policy views and positions, which collectively can be both related and unrelated to Pfizer’s business.

The Report describes how Pfizer’s PAC Steering Committee evaluates candidates on the basis of their views on the issues that impact Pfizer and considers their voting record on policies critical to Pfizer’s purpose. In addition, we disclose that contributions made to such recipients "do not imply an endorsement of a candidate’s position on any social or religious issue." The Governance & Sustainability Committee of the Pfizer Board is responsible for oversight of the company’s political spending policies and practices and receives periodic reports from management. The full Board is routinely informed of developments that could affect our risk profile or other aspects of our business.

Subsequent to the January 6, 2021 attack on the U.S. Capitol, we made the decision to freeze all contributions to the 147 Members of Congress who voted against certifying the results of the Electoral College, even after they had witnessed the unlawful attack on the U.S. Capitol. The freeze went into effect immediately for a period of six months, at which point we will review our decision. The Company’s action has nothing to do with party politics, but rather with the notion that the United States must remain a beacon of democracy where the rules of law are respected and valued. Pfizer recognizes that we all have a role to play in making our democracy work and that we all must come together to find ways to understand our differences and solve the problems we face constructively.

Q. Hello, I am an individual investor and shareholder. The focus of today’s meeting has been, understandably, about Covid-19. I would like to look beyond the pandemic and ask about Pfizer’s other new discoveries or drug pipeline that has major promise for future revenue growth and shareholder value. I apologize if this question has already been asked and addressed.

A. Thank you for inquiring about Pfizer’s pipeline and other new developments. While we invested significant time, resources and scientific expertise to find medical solutions to the pandemic, we continued to advance important work across all of our therapeutic areas. Please see below for several highlights:

May 10, 2021
- Our gene therapy platform has 3 programs currently in Phase 3 (Hemophilia B, Hemophilia A, Duchenne muscular dystrophy). We expect to conduct a planned interim analysis for a potential data readout in 2021 for Hemophilia B.
- Our JAK portfolio, including abrocitinib, currently under regulatory review for atopic dermatitis, and ritlecitinib, in Phase 3 for alopecia areata.
- Our vaccine portfolio (non-COVID), including vaccine candidates in Phase 3 for C. Difficile, meningitis ABCWY, RSV-Maternal, and our 20-valent pneumococcal conjugate vaccine candidate, or “20vPnC” for pediatric use as well as candidates in Phase 2 for Lyme disease and Group B Strep-Maternal.
- We are exploring a wide range of opportunities for mRNA technology.
- Our small molecule oral GLP-1 (danuglipron) in Phase 2 for diabetes/obesity.

In addition, Pfizer recently announced its 2021 first quarter financial results, please see PFE - 04.04.2021-EX 99 (q4cdn.com). The link to Pfizer’s current pipeline is provided below: Product Pipeline: Pharmaceutical Pipeline for New Drugs | pfizeruscom

Disclosure Notice: The information contained in this document is as of May 10, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This document contains forward-looking information about our expectations for Pfizer’s pipeline portfolio, including anticipated regulatory submissions, data read-outs, study starts, approvals, clinical trial results and other developing data that become available, revenue contribution, growth, performance, timing of exclusivity and potential benefits, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; risks associated with interim and preliminary data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when any drug applications, biologics license applications and/or emergency use authorization applications may be filed in any jurisdictions for any potential indication for Pfizer’s product candidates; whether and when any such applications that may be filed for any of Pfizer’s product candidates may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product's benefits outweigh its known risks and
determination of the product’s efficacy and, if approved, whether any such product candidates will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of Pfizer’s product candidates, including development of products or therapies by other companies; manufacturing capabilities or capacity; uncertainties regarding the ability to obtain recommendations from vaccine technical committees and other public health authorities and uncertainties regarding the commercial impact of any such recommendations; uncertainties regarding the impact of COVID-19 on Pfizer’s business, operations and financial results; and competitive developments.

A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.